ADVENTRX: Investors: Investor Relations Home

INVESTOR HOME

CORPORATE GOVERNANCE

STOCK INFORMATION

PRESS RELEASES

EVENTS

MEDIA

SEC FILINGS

ANALYSTS

INVESTOR FAQ

Investor Relations Home

Stock Quote

ANX (Common Stock)
Exchange	NYSE Amex (US Dollar)
Price	$0.69
Change (%)	0.07 (11.29%)
Volume	4,692,409
Data as of 01/27/12 3:59 p.m. ET Minimum 20 minute delay Refresh quote

Featured Report

2010 Annual Report

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever ADVENTRX Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Corporate Profile

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary product candidates.

The Company's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a novel detergent-free formulation the chemotherapy drug docetaxel (Taxoter... More >>
Recent News More >>
Date Title
12/01/11 ADVENTRX Meets with FDA to Discuss Development Plans for ANX-188
11/16/11 ADVENTRX Announces Closing of Public Offering
11/11/11 ADVENTRX Prices Public Offering of Stock
11/10/11 ADVENTRX Announces Public Offering of Stock
Upcoming Events More >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.